Background: Prostate cancer (PCa) is considered one of the major health threats facing males in Sudan. Prostate-specific antigen (PSA) test is the most important laboratory test used in the diagnosis of prostate cancer, the main disadvantage of PSA is its limited specificity, which triggered a lot of interest in development, more research on other markers such as serum human kallikrein-2 (KLK-2) and free prostate specific antigen (fPSA). Objectives: To evaluate the validity of serum kallikrein-2 (KLK-2) and free prostate specific antigen (fPSA) in the early detection of prostate cancer among Sudanese patients. Method: In this study seventy men were considered as a case subject, who were diagnosed as cancer prostate at Gezira Hospital for Renal Disease and Surgery (GHRDS), Sudan during the period February 2018 to July 2019. Randomly selected sixty patients of BPH patients and forty-five apparently healthy men as control subject. KLK-2, fPSA and PSA estimations were performed from serum samples using the principle of Enzyme Linked Immunosorbent Assay (ELISA). Results: The results revealed a highly significant difference between the serum levels individual biomarkers (KLK-2, fPSA, PSA) and multiple biomarkers (fPSA/PSA, KLK-2/fPSA, KLK-2/PSA) for patients with prostate cancer when compared with the control groups. Furthermore, the fPSA/PSA ratio was lower in the patients with prostate cancer (P value = 0.00) than in the control group, the fPSA/PSA ratio showed that best accuracy to differentiate prostate cancer from control group, fPSA cut-off value was found to be more than (18 ng/ml), with sensitivity (93%), specificity (80%), and odds ratio (55). Conclusions: The use of multiple biomarkers rather than individual biomarkers especially fPSA/PSA ratio improves the specificity as well as maintenance of higher sensitivity for early diagnosis of the prostate cancer.
References
[1]
Prajapati, A., Gupta, S., Mistry, B. and Gupta, S. (2013) Prostate Stem Cells in the Development of Benign Prostate Hyperplasia and Prostate Cancer: Emerging Role and Concepts. BioMed Research International, 2013, Article ID: 107954. https://doi.org/10.1155/2013/107954
[2]
Gorish, B.M.T., Ournasseir, M.E.H. and Shammat, I.M. (2019) A Correlation Study of BK Polyoma virus Infection and Prostate Cancer among Sudanese Patients-Immunofluorescence and Molecular Based Case-Control Study. Infectious Agents and Cancer, 14, Article No. 25. https://doi.org/10.1186/s13027-019-0244-7
[3]
Barsouk, A., Padala, S.A., Vakiti, A., Mohammed, A., Saginala, K., Thandra, K.C. and Barsouk, A. (2020) Epidemiology, Staging and Management of Prostate Cancer. Medical Sciences, 8, Article 28. https://doi.org/10.3390/medsci8030028
[4]
Panigrahi, G.K., Praharaj, P.P., Kittaka, H., Mridha, A.R., Black, O.M., Singh, R., et al. (2019) Exosome Proteomic Analyses Identify Inflammatory Phenotype and Novel Biomarkers in African American Prostate Cancer Patients. Cancer Medicine, 8, 1110-1123. https://doi.org/10.1002/cam4.1885
[5]
Abdullah, Y.M.Y. and Khalifa, A.A. (2015) Estimating Environmental and Occupational Factors that Contribute to Cancer in Sudan. International Journal of Health and Rehabilitation Sciences, 4, 115-121. https://doi.org/10.5455/ijhrs.000000081
[6]
Elamin, A., Ibrahim, M.E., Abuidris, D., Mohamed, K.E.H. and Mohammed, S.I. (2015) Part I: Cancer in Sudan—Burden, Distribution, and Trends Breast, Gynecological, and Prostate Cancers. Cancer Medicine, 4, 447-456. https://doi.org/10.1002/cam4.378
[7]
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492
[8]
Abuelgasim, A.E. (2016) The Role of Cytokeratin 5/6 in Differential Diagnosis of Prostate Tumors. European Academic Research, 3, 11551-11558.
[9]
Abeer, A.E. and Mohammed, O.M. (2003) Pathological Grading of Prostate Cancer in Sudanese Patients Attended Soba Teaching Hospital. University of Khartoum, Khartoum.
[10]
Ferlay, J., Ervik, M., Lam, F., Colombet, M., Mery, L., Piñeros, M., et al. (2018) Global Cancer Observatory: Cancer Today. International Agency for Research on Cancer, Lyon.
[11]
Soletormos, G., Semjonow, A., Sibley, P.E., Lamerz, R., Petersen, P.H., Albrecht, W., Bialk, P., Gion, M., Junker, F., Schmid, H.-P. and Poppel, H., on Behalf of the European Group on Tumor Markers (2005) Biological Variation of Total Prostate-Specific Antigen: A Survey of Published Estimates and Consequences for Clinical Practice. Clinical Chemistry, 51, 1342-1351. https://doi.org/10.1373/clinchem.2004.046086
[12]
Logozzi, M., Angelini, D.F., Iessi, E., Mizzoni, D., Di Raimo, R., Federici, C., et al. (2017) Increased PSA Expression on Prostate Cancer Exosomes in invitro Condition and in Cancer Patients. Cancer Letters, 403, 318-329. https://doi.org/10.1016/j.canlet.2017.06.036
[13]
Caplan, A. and Kratz, A. (2002) Prostate-Specific Antigen and the Early Diagnosis of Prostate Cancer. Pathology Patterns Reviews, 117, S104-S108. https://doi.org/10.1309/C4UN-12LK-43HP-JXY3
[14]
Qaseem, A., Barry, M.J., Denberg, T.D., Owens, D.K., Shekelle, P. and Clinical Guidelines Committee of the American College of Physicians. (2013) Screening for Prostate Cancer: A Guidance Statement from the Clinical Guidelines Committee of the American College of Physicians. Annals of Internal Medicine, 158, 761-769. https://doi.org/10.7326/0003-4819-158-10-201305210-00633
[15]
Moyer, V.A. and US Preventive Services Task Force (2012) Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 157, 120-134. https://doi.org/10.7326/0003-4819-157-2-201207170-00459
[16]
Ewenighi, C., Dimkpa, U., Onyeanusi, J., Onoh, L., Onoh, G., Oti, N., Onyeanusi, L. and Ezeugwu, U. (2015) Use of Free-Total Prostate Specific Antigen Ratio in Screening Prostate Cancer in Men with Specific Elevations of Prostate Specific Antigen. THE Ulutas Medical Journal, 1, 31-35. https://doi.org/10.5455/umj.20150518015721
[17]
Hoffman, R.M., Clanon, D.L., Littenberg, B., Frank, J.J. and Peirce, J.C. (2000) Using the Free-to-Total Prostate-Specific Antigen Ratio to Detect Prostate Cancer in Men with Nonspecific Elevations of Prostate‐Specific Antigen Levels. Journal of General Internal Medicine, 15, 739-748. https://doi.org/10.1046/j.1525-1497.2000.90907.x
[18]
Ahmad, S., Ghafar, A. and Khan, G. (2017) Free/Total Prostate Specific Antigen Ratio as Predictor for Prostate Carcinoma. Gomal Journal of Medical Sciences, 15, 30-33.
[19]
Mwirigi, L.K. (2015) The Cytokine Profile and Prostate Specific Antigen Levels in Prostate Cancer Patients at Kenyatta National Hospital. Doctoral Dissertation, Kenyatta University, Kahawa.
[20]
BjÖrk, T., Nilsson, O., Dahlén, U., Matikainen, M.T., Cockett, A.T., Abrahamsson, P.A. and Lilja, H. (1993) Serum Prostate Specific Antigen Complexed to α1-Anti-chymotrypsin as an Indicator of Prostate Cancer. The Journal of Urology, 150, 100-105. https://doi.org/10.1016/S0022-5347(17)35408-3
[21]
Jung, K., Elgeti, U., Lein, M., Brux, B., Sinha, P., Rudolph, B. and Loening, S.A. (2000) Ratio of Free or Complexed Prostate-Specific Antigen (PSA) to Total PSA: Which Ratio Improves Differentiation between Benign Prostatic Hyperplasia and Prostate Cancer? Clinical Chemistry, 46, 55-62. https://doi.org/10.1016/S0022-5347(17)35408-3
[22]
Balk, S.P., Ko, Y.J. and Bubley, G.J. (2003) Biology of Prostate-Specific Antigen. Journal of Clinical Oncology, 21, 383-391. https://doi.org/10.1200/JCO.2003.02.083
[23]
Satkunasivam, R., Zhang, W., Trachtenberg, J., Toi, A., Yu, C., Diamandis, E., Kattan, M.W., Narod, S.A. and Nam, R.K. (2014) Human Kallikrein-2 Gene and Protein Expression Predicts Prostate Cancer at Repeat Biopsy. SpringerPlus, 3, Article No. 295. https://doi.org/10.1186/2193-1801-3-295
[24]
Taha, S.M., Weng, H.Y., Mohammed, M.E.I., Osman, Y.M., Mohammed, S.I. and Abuidris, D.O. (2020) Prostate Cancer Clinical Characteristics and Outcomes in Centeral Sudan. Ecancer, 14, Article ID: 1116. https://doi.org/10.3332/ecancer.2020.1116
[25]
Bachour, D.M., Chahin, E. and Al-Fahoum, S. (2015) Human Kallikrein-2, Prostate Specific Antigen and Free-Prostate Specific Antigen in Combination to Discriminate Prostate Cancer from Benign Diseases in Syrian Patients. Asian Pacific Journal of Cancer Prevention, 16, 7085-7088. https://doi.org/10.7314/APJCP.2015.16.16.7085
[26]
Cao, Y., Zhang, W., Li, Y., Fu, J., Li, H., Li, X., Gao, X., Zhang, K. and Liu, S. (2021) Rates and Trends in Stage-Specific Prostate Cancer Incidence by Age and Race/ Ethnicity, 2000-2017. The Prostate, 81, 1071-1077. https://doi.org/10.1002/pros.24204
[27]
Williams, S.A., Singh, P., Isaacs, J.T. and Denmeade, S.R. (2007) Does PSA Play a Role as a Promoting Agent during the Initiation and/or Progression of Prostate Cancer? The Prostate, 67, 312-329. https://doi.org/10.1002/pros.20531
[28]
Stephan, C., Jung, K., Lein, M., Sinha, P., Schnorr, D. and Loening, S.A. (2000) Molecular Forms of Prostate-Specific Antigen and Human Kallikrein 2 as Promising Tools for Early Diagnosis of Prostate Cancer. Cancer Epidemiology Biomarkers & Prevention, 9, 1133-1147.
[29]
Benson, M.C., Whang, I.S., Pantuck, A., Ring, K., Kaplan, S.A., Olsson, C.A. and Cooner, W.H. (1992) Prostate Specific Antigen Density: A Means of Distinguishing Benign Prostatic Hypertrophy and Prostate Cancer. The Journal of Urology, 147, 815-816. https://doi.org/10.1016/S0022-5347(17)37393-7
[30]
Hussein, A.A., Baban, R. and Hussein, A. (2020) Prostate-Specific Antigen and Free Prostate-Specific Antigen/Prostate-Specific Antigen Ratio in Patients with Benign Prostatic Hyperplasia and Prostate Cancer. Baghdad Journal of Biochemistry and Applied Biological Sciences, 1, 18-26. https://doi.org/10.47419/bjbabs.v1i01.28
[31]
Stephan, C., Jung, K., Nakamura, T., Yousef, G.M., Kristiansen, G. and Diamandis, E.P. (2006) Serum Human Glandular Kallikrein 2 (hK2) for Distinguishing Stage and Grade of Prostate Cancer. International Journal of Urology, 13, 238-243. https://doi.org/10.1111/j.1442-2042.2006.01276.x
[32]
Timmermand, O.V., Ulmert, D., Evans-Axelsson, S., Pettersson, K., Bjartell, A., Lilja, H., Strand, S.-E. and Tran, T.A. (2014) Preclinical Imaging of Kallikrein-Related Peptidase 2 (hK2) in Prostate Cancer with a 111In-Radiolabelled Monoclonal Antibody, 11B6. EJNMMI Research, 4, Article No. 51. https://doi.org/10.1186/s13550-014-0051-5
[33]
Kwiatkowski, M.K., Recker, F., Piironen, T., Pettersson, K., Otto, T., Wernli, M. and Tscholl, R. (1998) In Prostatism Patients the Ratio of Human Glandular Kallikrein to Free PSA Improves the Discrimination between Prostate Cancer and Benign Hyperplasia within the Diagnostic “Gray Zone” of Total PSA 4 to 10 ng/mL. Urology, 52, 360-365. https://doi.org/10.1016/S0090-4295(98)00245-3
[34]
Agyei-Frempong, M.T., Frempong, N.Y., Aboah, K. and Boateng, K.A. (2008) Correlation of Serum Free/Total Prostate Specific Antien Ratio with Histological Features for Differential Diagnosis of Prostate Cancer. Journal of Medical Sciences, 8, 540-546. https://doi.org/10.3923/jms.2008.540.546
[35]
Ceylan, C., Gazel, E., Keleş, I., Doluoğlu, Ö. and Yığman, M. (2015) Can the Free/ Total PSA Ratio Predict the Gleason Score before Prostate Biopsy? Current Urology, 9, 24-27. https://doi.org/10.1159/000442846
